source
- Tyra Biosciences shares tumble as bladder cancer pill shows lower-than-expected complete responseTyra Biosciences presented Phase 2 SURF302 data for its investigational oral drug dabogratinib in patients with low‑grade intermediate‑risk non‑muscle invasive bladder cancer. The trial reported th…
- UniQure to release four-year Huntington’s gene therapy results by SeptemberUniQure, a biotech firm, will report four-year data from its Huntington’s disease gene therapy trial before the end of September. The therapy, AMT-130, has already been submitted to regulators in…